
Substantial protection against MPTP-associated Parkinson's neurotoxicity in vitro and in vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B
Keywords: Parkinson's disease; SU4312; Neuroprotection; Myocyte enhancer factor 2D; Monoamine oxidase-B; AD; Alzheimer's disease; CDKs; cyclin-dependent kinases; DMEM; Dulbecco's modified Eagle's medium; FBS; fetal bovine serum; GSK3β; glycogen synthase kinase 3β